The U.S. Food and Drug Administration has granted tentative approval to Dr. Reddy’s Laboratories for a generic version of lenacapavir, the twice-yearly injectable medicine used to prevent HIV infection.
The decision is seen as a key step toward wider access in low- and middle-income countries, where the generic is expected to cost about 40 US dollars per person per year — comparable to daily preventive tablets. The brand-name product is marketed by Gilead Sciences.
Source: STAT News















